Showing 2641–2652 of 3002 results

  • SYNGAB 50MG CAP

    SYNGAB 50MG CAP

    0 out of 5
    242.62

    Syngab 50 mg Capsule contains Pregabalin, an anticonvulsant and neuropathic pain reliever used to treat nerve pain, fibromyalgia, and partial seizures. It works by reducing abnormal electrical activity in the brain and calming overactive nerves to relieve pain and prevent seizures.

  • SYNGAB 50MG CAP

    SYNGAB 50MG CAP

    0 out of 5
    421

    Syngab 50 mg Capsule contains Pregabalin, an anticonvulsant and neuropathic pain reliever used to treat nerve pain, fibromyalgia, and partial seizures. It works by reducing abnormal electrical activity in the brain and calming overactive nerves to relieve pain and prevent seizures.

  • SYNGAB 75MG CAP

    SYNGAB 75MG CAP

    0 out of 5
    500

    Syngab 75 mg Capsule contains Pregabalin, an anticonvulsant and neuropathic pain reliever used to manage nerve pain, fibromyalgia, and certain types of seizures. It works by calming overactive nerves and reducing abnormal brain activity, which helps relieve pain and prevent seizures.

  • T-Day 120mL Syrup

    T-Day 120mL Syrup

    0 out of 5
    150

    T-Day Syrup contains Desloratadine, an antihistamine used to relieve allergy symptoms such as runny nose, sneezing, watery eyes, and itching.

  • T-Day Tablet (30s)

    T-Day Tablet (30s)

    0 out of 5
    360

    T-Day Tablet also contains Desloratadine (antihistamine) and is used to treat allergy symptoms like hay fever, sneezing, runny nose, and itchy eyes/nose.

  • Tagip 100mg Tablet (14s)

    Tagip 100mg Tablet (14s)

    0 out of 5
    602

    Tagip 100mg Tablet contains Sitagliptin, an oral antidiabetic medicine (DPP-4 inhibitor) used to control blood sugar levels in type 2 diabetes, often in combination with other diabetes medicines.

  • TAGIP 25MG TAB (14S)

    TAGIP 25MG TAB (14S)

    0 out of 5
    280

    Tagip 25mg Tablet contains Sitagliptin, an oral antidiabetic medicine used for the treatment of type 2 diabetes mellitus. It belongs to the DPP-4 inhibitor class, which works by increasing insulin release and decreasing glucose production in the body. It helps control blood sugar levels, especially after meals, and lowers the risk of diabetes-related complications when…

  • Tagip 50mg Tablet (14s)

    Tagip 50mg Tablet (14s)

    0 out of 5
    434

    Tagip 50mg Tablet also contains Sitagliptin and is used for the management of type 2 diabetes mellitus by improving blood sugar control.

  • TAGIPMET 50/500 mg Tablet (20s)

    TAGIPMET 50/500 mg Tablet (20s)

    0 out of 5
    760

    Tagipmet 50/500 mg Tablet combines Sitagliptin (50 mg) and Metformin (500 mg) to help manage blood glucose levels in type 2 diabetes, improving insulin response and lowering excess sugar production.

  • TAGIPMET XR 100/1000 mg Tablet

    TAGIPMET XR 100/1000 mg Tablet

    0 out of 5
    880

    100/1000 mg Tablet is an extended-release (XR) formulation containing Sitagliptin (100 mg) and Metformin (1000 mg), used for better long-term control of blood sugar in type 2 diabetes with once-daily dosing.

  • TAGIPMET XR 100/500MG TAB

    TAGIPMET XR 100/500MG TAB

    0 out of 5

    TAGIPMET XR 100/500MG TAB is an extended-release, combination medication used to treat type 2 diabetes mellitus. It contains two active ingredients: sitagliptin (100mg) and metformin (500mg). Sitagliptin is a DPP-4 inhibitor that helps to increase insulin production and decrease glucose from the liver after meals. Metformin is a biguanide that reduces glucose production in the…

  • TAGIPMET XR 50/1000 mg Tablet

    TAGIPMET XR 50/1000 mg Tablet

    0 out of 5
    362.60

    This pack of Tagipmet XR 50/1000 mg (20s) also contains Sitagliptin and Metformin (extended-release), used to manage type 2 diabetes by controlling blood glucose levels throughout the day.

End of content

End of content

The Categories provide a framework to which existing art information systems can be mapped and upon which new systems can be developed. In addition, the discussions in the CDWA identify vocabulary resources and descriptive practices that will make information residing in diverse systems both more compatible and more accessible.The use of the CDWA framework will contribute to the integrity and longevity of data and will facilitate its inevitable migration to new systems as informational technology continues to evolve. Above all, it will help to give end-users consistent, reliable access to information, regardless of the system in which it resides.